BioAtla, Inc. (BCAB)
Company Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 56 |
Contact Details
Address:
11085 Torreyana Road San Diego, CA 92121 United States | |
| Phone | 858 558 0708 |
| Website | bioatla.com |
Stock Details
| Ticker Symbol | BCAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $18.00 |
| CIK Code | 0001826892 |
| ISIN Number | US09077B1044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Scott Andrew Smith | President and Director |
| Richard A. Waldron | Chief Financial Officer |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Christian Vasquez | Vice President of Finance, Corporate Controller and Secretary |
| Philippe Martin | Chief Clinical Development and Operations |
| Lisa M. Pelton | Accounting Manager |
| Susie Melody | Senior Vice President of Human Resources |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development |
| Monica Sullivan | Senior Vice President of Intellectual Property and Contracts |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 22, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4/A | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 8-K | Current report |
| Jun 10, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |